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Image in medicine 
 
A 40-year-old HIV-positive female presented with an erythematous 
macular eruption involving the malar and periorbital area, the 
forehead and neck of six weeks of duration (A). She had initiated 
antiretroviral treatment with co-formulated 
tenofovir/lamivudine/efavirenz QD plus isoniazid preventive therapy 
(IPT) 18 weeks before with CD4 counts of 496 cells/μl (25%). Drug-
induced subacute cutaneous lupus erythematous (DI-SCLE) 
secondary to isoniazid was clinically diagnosed and isoniazid was 
stopped. Antinuclear antibody (ANA), anti-SSA/Ro, anti-SSB/La, 
anti-Sm, anti-RNP and antihistone antibodies were negative. 
Complete blood count, eGFR and liver transaminases were normal. 
Three months after stopping isoniazid, the skin lesions resolved 
completely, supporting the diagnosis of isoniazid-induced SCLE (B). 
DI-SCLE with negative ANA has been described, but there are no 
reports in HIV-infected patients. With the current expanded 
provision of IPT to people living with HIV, it is important to be 
aware of this rare side effect of isoniazid despite the negativity of 
antibody assays. 
 
 
 
Figure 1: (A) malar, periorbital and forehead macular eruption 
after starting antiretroviral drugs and isoniazid preventive 
therapy; (B) a clear skin three months after stopping isoniazid 
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